SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) MARCH 25, 2004
--------------
INTERPHARM HOLDINGS, INC.
--------------------------------------------------
(Exact name of Registrant as specified in charter)
Delaware 0-22710 13-3673965
------------------------- ------------ -------------------
(State or other jurisdic- (Commission (IRS Employer
tion of incorporation) File Number) Identification No.)
69 Mall Drive, Commack, New York 11725
----------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (631) 543-2800
--------------
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
On March 25, 2004, Bhupatlal K. Sutaria, an Interpharm Holdings, Inc.
(the "Company") Director and its President, and Praveen Bhutani, a Director,
resigned their directorships. Mr. Sutaria resigned his directorship in order to
enable him to focus solely on his responsibilities as President of the Company.
Mr. Bhutani resigned in order to pursue other interests. Neither Mr. Sutaria's,
nor Mr. Bhutani's resignation was the result of any disagreement with the
Company, its officers or directors regarding its operations, policies,
practices, public reports or disclosures.
At a Board of Directors meeting held on March 25, 2004, the Company
accepted the resignations of Messrs. Sutaria and Bhutani and appointed Dr. Mark
Goodman and James Charles to the Board of Directors.
Dr. Goodman has been a cardiologist for more than 30 years and is
currently in private practice and is affiliated with Winthrop University
Hospital in Mineola, New York and North Shore University Hospital in Manhasset,
New York. Dr. Goodman has participated in a number of drug trials as a primary
investigator for a number of drug companies, including, Pfizer, Ciba
Pharmaceuticals and Kos Pharmaceuticals. Dr. Goodman has also served on advisory
panels to Medtronic Pacemaker Corporation and Bristol-Myers Squibb Company.
Mr. Charles served as the Company's Chief Financial Officer from
January, 1999 through January, 2004. Prior to his service with the Company, Mr.
Charles was a financial consultant to several public companies from 1994 through
1998. Mr. Charles was also the Chief Financial Officer of a printing company
from 1991-1994 and a partner at Ernst & Young from 1966-1991.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERPHARM HOLDINGS, INC.
April 20, 2004 By: /S/ GEORGE ARONOSON
-----------------------------------
George Aronson
Chief Financial Officer